CY1119705T1 - Νεα παραγωγα αμινοπυριμιδινης - Google Patents

Νεα παραγωγα αμινοπυριμιδινης

Info

Publication number
CY1119705T1
CY1119705T1 CY20171101345T CY171101345T CY1119705T1 CY 1119705 T1 CY1119705 T1 CY 1119705T1 CY 20171101345 T CY20171101345 T CY 20171101345T CY 171101345 T CY171101345 T CY 171101345T CY 1119705 T1 CY1119705 T1 CY 1119705T1
Authority
CY
Cyprus
Prior art keywords
diseases
novel amino
aminopyrimidine derivatives
new
bruton
Prior art date
Application number
CY20171101345T
Other languages
English (en)
Inventor
Daniela Angst
François GESSIER
Anna Vulpetti
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1119705T1 publication Critical patent/CY1119705T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

Η παρούσα εφεύρεση περιγράφει νέα παράγωγα αμινο πυριμιδίνης του χημικού τύπου (I) και φαρμακευτικά αποδεκτά άλατα αυτού τα οποία φαίνεται να αλληλεπιδρούν με την τυροσινική κινάση του Bruton (Btk). Αντίστοιχα, οι νέες αμινο πυριμιδίνες μπορεί να είναι αποτελεσματικές στη θεραπεία αυτοάνοσων διαταραχών, φλεγμονωδών νόσων, αλλεργικών νόσων, νόσων των αεραγωγών, όπως είναι το άσθμα και η χρόνια αναπνευστική πνευμονοπάθεια (ΧΑΠ), η απόρριψη μοσχεύματος, διάφορες μορφές καρκίνου, π.χ. αιματοποιητικής προέλευσης ή στέρεοι όγκοι.
CY20171101345T 2013-11-29 2017-12-22 Νεα παραγωγα αμινοπυριμιδινης CY1119705T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13195081 2013-11-29
EP14821285.5A EP3074386B1 (en) 2013-11-29 2014-11-28 Novel amino pyrimidine derivatives
PCT/IB2014/066422 WO2015079417A1 (en) 2013-11-29 2014-11-28 Novel amino pyrimidine derivatives

Publications (1)

Publication Number Publication Date
CY1119705T1 true CY1119705T1 (el) 2018-06-27

Family

ID=49674216

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20171101345T CY1119705T1 (el) 2013-11-29 2017-12-22 Νεα παραγωγα αμινοπυριμιδινης
CY20201100478T CY1122924T1 (el) 2013-11-29 2020-05-25 Νεα παραγωγα αμινοπυριμιδινης
CY20231100301T CY1126056T1 (el) 2013-11-29 2023-06-27 Νεα παραγωγα αμινοπυριμιδινης

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY20201100478T CY1122924T1 (el) 2013-11-29 2020-05-25 Νεα παραγωγα αμινοπυριμιδινης
CY20231100301T CY1126056T1 (el) 2013-11-29 2023-06-27 Νεα παραγωγα αμινοπυριμιδινης

Country Status (43)

Country Link
US (6) US9512084B2 (el)
EP (4) EP3074386B1 (el)
JP (2) JP6342495B2 (el)
KR (2) KR102421388B1 (el)
CN (2) CN105683181B (el)
AP (1) AP2016009158A0 (el)
AR (1) AR098549A1 (el)
AU (1) AU2014356069B2 (el)
BR (1) BR112016010397B1 (el)
CA (1) CA2926908C (el)
CL (1) CL2016001055A1 (el)
CR (1) CR20160244A (el)
CU (1) CU24384B1 (el)
CY (3) CY1119705T1 (el)
DK (3) DK3689865T3 (el)
EA (1) EA031218B1 (el)
EC (1) ECSP16054826A (el)
ES (3) ES2655527T3 (el)
FI (1) FI3689865T3 (el)
HK (2) HK1223368A1 (el)
HR (3) HRP20230585T1 (el)
HU (3) HUE062248T2 (el)
IL (1) IL244943B (el)
JO (1) JO3314B1 (el)
LT (3) LT3689865T (el)
MA (1) MA39055B1 (el)
MX (1) MX367911B (el)
MY (2) MY179059A (el)
NO (1) NO3074386T3 (el)
NZ (1) NZ718835A (el)
PE (1) PE20160869A1 (el)
PH (1) PH12016500791B1 (el)
PL (3) PL3689865T3 (el)
PT (3) PT3689865T (el)
RS (3) RS56657B1 (el)
SI (3) SI3074386T1 (el)
SV (1) SV2016005206A (el)
TN (1) TN2016000128A1 (el)
TW (1) TWI652261B (el)
UA (1) UA117256C2 (el)
UY (1) UY35858A (el)
WO (1) WO2015079417A1 (el)
ZA (1) ZA201602275B (el)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
DK3129470T3 (da) 2014-04-07 2021-07-05 Novartis Ag Behandling af cancer ved anvendelse af anti-CD19-kimær antigenreceptor
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
KR102612313B1 (ko) 2014-07-21 2023-12-12 노파르티스 아게 인간화 항-bcma 키메라 항원 수용체를 사용한 암의 치료
KR102594343B1 (ko) 2014-07-21 2023-10-26 노파르티스 아게 Cd33 키메라 항원 수용체를 사용한 암의 치료
EP4205749A1 (en) 2014-07-31 2023-07-05 Novartis AG Subset-optimized chimeric antigen receptor-containing cells
EP3180359A1 (en) 2014-08-14 2017-06-21 Novartis AG Treatment of cancer using gfr alpha-4 chimeric antigen receptor
SG11201700770PA (en) 2014-08-19 2017-03-30 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
AU2015317608B2 (en) 2014-09-17 2021-03-11 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CN106973568B (zh) 2014-10-08 2021-07-23 诺华股份有限公司 预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途
ES2952717T3 (es) 2014-10-14 2023-11-03 Novartis Ag Moléculas de anticuerpos contra PD-L1 y usos de las mismas
WO2016090034A2 (en) 2014-12-03 2016-06-09 Novartis Ag Methods for b cell preconditioning in car therapy
ES2876974T3 (es) * 2015-04-07 2021-11-15 Novartis Ag Combinación de terapia con receptor de antígeno quimérico y derivados de amino pirimidina
KR20170134642A (ko) 2015-04-08 2017-12-06 노파르티스 아게 Cd20 요법, cd22 요법, 및 cd19 키메라 항원 수용체 (car) - 발현 세포와의 조합 요법
CN114272371A (zh) 2015-07-29 2022-04-05 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
LT3317301T (lt) 2015-07-29 2021-07-26 Novartis Ag Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3
EP3389712B1 (en) 2015-12-17 2024-04-10 Novartis AG Antibody molecules to pd-1 and uses thereof
WO2017112741A1 (en) 2015-12-22 2017-06-29 Novartis Ag Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
EP3423482A1 (en) 2016-03-04 2019-01-09 Novartis AG Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
WO2018017708A1 (en) 2016-07-20 2018-01-25 University Of Utah Research Foundation Cd229 car t cells and methods of use thereof
US10525083B2 (en) 2016-10-07 2020-01-07 Novartis Ag Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain
CA3045355A1 (en) 2016-12-03 2018-06-07 Juno Therapeutics, Inc. Methods for determining car-t cells dosing
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
AU2018275894A1 (en) 2017-06-02 2019-12-12 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
EP3644721A1 (en) 2017-06-29 2020-05-06 Juno Therapeutics, Inc. Mouse model for assessing toxicities associated with immunotherapies
US11066475B2 (en) 2017-11-01 2021-07-20 Juno Therapeutics, Inc. Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides
US20210132042A1 (en) 2017-11-01 2021-05-06 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
US11623961B2 (en) 2017-11-01 2023-04-11 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for B-cell maturation antigen
TWI694995B (zh) * 2017-11-06 2020-06-01 美商美國禮來大藥廠 Btk抑制劑化合物
CN111989106A (zh) 2017-12-01 2020-11-24 朱诺治疗学股份有限公司 基因工程化细胞的给药和调节方法
CN108069911A (zh) * 2017-12-14 2018-05-25 中国药科大学 6－氨基－2－苯基嘧啶类化合物、制备方法和医药用途
MA51184A (fr) 2017-12-15 2020-10-21 Juno Therapeutics Inc Molécules de liaison à l'anti-cct5 et procédés d'utilisation associés
EP3788369A1 (en) 2018-05-01 2021-03-10 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
WO2019227003A1 (en) 2018-05-25 2019-11-28 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
BR112020025048A2 (pt) 2018-06-13 2021-04-06 Novartis Ag Receptores de antígeno quimérico de bcma e usos dos mesmos
MA53388A (fr) 2018-07-25 2021-06-02 Novartis Ag Inhibiteurs d'inflammasome nlrp3
US20210393689A1 (en) 2018-11-01 2021-12-23 Juno Therapeutics, Inc. Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d)
CN113646335A (zh) 2018-11-01 2021-11-12 朱诺治疗学股份有限公司 使用对b细胞成熟抗原具有特异性的嵌合抗原受体的治疗的方法
EP3880238A1 (en) 2018-11-16 2021-09-22 Juno Therapeutics, Inc. Methods of dosing engineered t cells for the treatment of b cell malignancies
JP2022513685A (ja) 2018-11-30 2022-02-09 ジュノー セラピューティクス インコーポレイテッド 養子細胞療法を用いた処置のための方法
PE20212198A1 (es) 2019-01-29 2021-11-16 Juno Therapeutics Inc Anticuerpos y receptores quimericos de antigenos especificos para receptor 1 huerfano tipo receptor tirosina-cinasa (ror1)
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
JP2022533981A (ja) * 2019-05-23 2022-07-27 ノバルティス アーゲー ブルトン型チロシンキナーゼ阻害薬を用いて慢性自発性蕁麻疹を治療する方法
WO2020234780A1 (en) 2019-05-23 2020-11-26 Novartis Ag Methods of treating asthma using a bruton's tyrosine kinase inhibitor
MX2021014161A (es) 2019-05-23 2022-01-04 Novartis Ag Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton.
CA3137790A1 (en) 2019-05-23 2020-11-26 Novartis Ag Crystalline forms of a btk inhibitor
JP2023508394A (ja) * 2019-12-23 2023-03-02 バイオジェン・エムエイ・インコーポレイテッド Ｂｔｋ阻害剤
KR20230009386A (ko) 2020-04-10 2023-01-17 주노 쎄러퓨티크스 인코퍼레이티드 Ｂ-세포 성숙 항원을 표적화하는 키메라 항원 수용체로 조작된 세포 요법 관련 방법 및 용도
WO2022033569A1 (zh) * 2020-08-14 2022-02-17 苏州晶云药物科技股份有限公司 苯甲酰胺类化合物的晶型及其制备方法
US11708366B2 (en) 2020-08-14 2023-07-25 Novartis Ag Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof
TW202245778A (zh) 2021-01-26 2022-12-01 瑞士商諾華公司 藥物組成物
WO2022212893A1 (en) 2021-04-02 2022-10-06 Biogen Ma Inc. Combination treatment methods of multiple sclerosis
KR20240055038A (ko) 2021-09-03 2024-04-26 노파르티스 아게 다발성 경화증 치료를 위한 lou064
WO2023111802A1 (en) 2021-12-14 2023-06-22 Novartis Ag Methods of treatment using lou064
TW202342048A (zh) 2022-02-28 2023-11-01 瑞士商諾華公司 使用ｌｏｕ０６４治療化膿性汗腺炎之方法
WO2023250400A1 (en) 2022-06-22 2023-12-28 Juno Therapeutics, Inc. Treatment methods for second line therapy of cd19-targeted car t cells
US20240067627A1 (en) 2022-08-03 2024-02-29 Novartis Ag Nlrp3 inflammasome inhibitors
US20240041929A1 (en) 2022-08-05 2024-02-08 Juno Therapeutics, Inc. Chimeric antigen receptors specific for gprc5d and bcma
WO2024069507A1 (en) 2022-09-30 2024-04-04 Novartis Ag Synthesis methods and intermediates for the production of remibrutinib
CN117024354B (zh) * 2023-10-08 2023-12-08 天津凯莱英制药有限公司 瑞米布替尼的制备方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303652B1 (en) 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
GB0005345D0 (en) 2000-03-06 2000-04-26 Mathilda & Terence Kennedy Ins Methods of treating sepsis septic shock and inflammation
CA2426508A1 (en) 2000-10-23 2002-05-16 Bristol-Myers Squibb Company Modulators of bruton's tyrosine kinase and bruton's tyrosine kinase intermediates and methods for their identification and use in the treatment and prevention of osteoporosis and related disease states
NZ525656A (en) 2000-11-07 2004-12-24 Novartis Ag Indolylmaleimide derivatives as protein kinase C inhibitors
AR036053A1 (es) 2001-06-15 2004-08-04 Versicor Inc Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas
TW200918046A (en) 2002-04-03 2009-05-01 Novartis Ag Indolylmaleimide derivatives
EP2322201A3 (en) 2002-10-29 2011-07-27 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7365096B2 (en) 2002-12-09 2008-04-29 Board Of Regents, The University Of Texas System Methods for selectively inhibiting Janus tyrosine kinase 3 (Jak3)
EP1631260A2 (en) 2003-02-28 2006-03-08 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
EP1473039A1 (en) 2003-05-02 2004-11-03 Centre National De La Recherche Scientifique (Cnrs) Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis
PE20050158A1 (es) 2003-05-19 2005-05-12 Irm Llc Compuestos inmunosupresores y composiciones
ZA200602666B (en) 2004-01-12 2007-09-26 Cytopia Res Pty Ltd Selective kinase inhibitors
ES2543607T3 (es) 2005-03-10 2015-08-20 Gilead Connecticut, Inc. Ciertas amidas sustituidas, método de obtención, y método de su uso
AR063946A1 (es) * 2006-09-11 2009-03-04 Cgi Pharmaceuticals Inc Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
JP2010502751A (ja) 2006-09-11 2010-01-28 シージーアイ ファーマシューティカルズ，インコーポレイティド キナーゼ阻害物質、およびキナーゼ阻害物質の使用および同定方法
DK2081435T3 (en) 2006-09-22 2016-08-15 Pharmacyclics Llc INHIBITORS OF BRUTON'S TYROSINKINASE
US8232085B2 (en) 2007-03-14 2012-07-31 Bionsil S.R.L. Isoform of bruton's tyrosine kinase (BTK) protein
EP2297105B1 (en) 2008-05-06 2015-09-02 Gilead Connecticut, Inc. Substituted amides, method of making, and use as btk inhibitors
EP2300459B1 (en) 2008-07-02 2013-05-29 F. Hoffmann-La Roche AG Novel phenylpyrazinones as kinase inhibitors
ES2660418T3 (es) 2008-07-16 2018-03-22 Pharmacyclics Llc Inhibidores de la tirosina quinasa de Bruton para el tratamiento de tumores sólidos
US20100261776A1 (en) 2008-11-07 2010-10-14 The Research Foundation Of State University Of New York Bruton's tyrosine kinase as anti-cancer drug target
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
CN102292329B (zh) 2009-04-24 2014-09-03 霍夫曼-拉罗奇有限公司 布鲁顿酪氨酸激酶的抑制剂
WO2011104340A1 (en) * 2010-02-26 2011-09-01 Boehringer Ingelheim International Gmbh Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions
UY33241A (es) * 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
US20120071497A1 (en) 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
CN103889962B (zh) 2011-04-01 2017-05-03 犹他大学研究基金会 作为受体酪氨酸激酶btk抑制剂的取代的n‑(3‑(嘧啶‑4‑基)苯基)丙烯酰胺类似物
CN103717602B (zh) 2011-05-17 2016-11-09 加利福尼亚大学董事会 激酶抑制剂
SG194219A1 (en) 2011-06-10 2013-11-29 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
AU2012275275A1 (en) 2011-06-28 2014-01-23 Pharmacyclics Llc Methods and compositions for inhibition of bone resorption
EP2729466B1 (en) 2011-07-08 2015-08-19 Novartis AG Novel pyrrolo pyrimidine derivatives
US9273317B2 (en) 2011-08-09 2016-03-01 Fred Hutchinson Cancer Research Center Methods and compositions for inhibiting the growth and/or proliferation of MYC-driven tumor cells
CN110801454A (zh) 2011-10-19 2020-02-18 药品循环有限责任公司 布鲁顿酪氨酸激酶(btk)抑制剂的用途
JP2014532658A (ja) 2011-10-28 2014-12-08 セルジーン アヴィロミクス リサーチ， インコーポレイテッド ブルトン型チロシンキナーゼ疾患または障害を治療する方法
KR101673728B1 (ko) 2011-12-09 2016-11-07 에프. 호프만-라 로슈 아게 브루톤 티로신 키나아제의 억제제
EP2824099A4 (en) 2012-03-09 2015-11-11 Carna Biosciences Inc NOVEL TRIAZINE DERIVATIVE
CN104662018B (zh) 2012-04-20 2017-10-24 阿迪维纳斯治疗有限公司 取代的杂双环化合物、组合物及其医疗应用
WO2013157021A1 (en) 2012-04-20 2013-10-24 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
WO2013173518A1 (en) 2012-05-16 2013-11-21 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
AU2013299557B2 (en) 2012-08-10 2017-06-22 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as Bruton's tyrosine kinase (BTK) inhibitors
EP3680238A1 (en) 2012-10-04 2020-07-15 University of Utah Research Foundation Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives

Also Published As

Publication number Publication date
HK1223368A1 (zh) 2017-07-28
SI3074386T1 (en) 2018-02-28
CY1126056T1 (el) 2023-11-15
US11673868B2 (en) 2023-06-13
MX2016006908A (es) 2016-08-17
RS60251B1 (sr) 2020-06-30
HUE049794T2 (hu) 2020-10-28
IL244943B (en) 2020-04-30
EA031218B1 (ru) 2018-12-28
PL3074386T3 (pl) 2018-03-30
RS56657B1 (sr) 2018-03-30
US10457647B2 (en) 2019-10-29
CY1122924T1 (el) 2021-10-29
CR20160244A (es) 2016-07-29
PT3689865T (pt) 2023-06-16
ES2655527T3 (es) 2018-02-20
CU20160078A7 (es) 2016-09-30
CN110172056A (zh) 2019-08-27
MA39055B1 (fr) 2018-10-31
NO3074386T3 (el) 2018-03-10
CN105683181B (zh) 2019-04-23
US20200010426A1 (en) 2020-01-09
JP6667573B2 (ja) 2020-03-18
AR098549A1 (es) 2016-06-01
MY179059A (en) 2020-10-26
PL3299368T3 (pl) 2020-08-10
HUE062248T2 (hu) 2023-10-28
EP3074386A1 (en) 2016-10-05
PT3299368T (pt) 2020-05-28
PH12016500791A1 (en) 2016-06-13
FI3689865T3 (fi) 2023-06-12
JP2018141005A (ja) 2018-09-13
US11180460B2 (en) 2021-11-23
EP3689865B1 (en) 2023-03-29
PL3689865T3 (pl) 2023-07-31
US20230312483A1 (en) 2023-10-05
CA2926908C (en) 2021-10-26
US9512084B2 (en) 2016-12-06
ECSP16054826A (es) 2017-10-31
KR20160088877A (ko) 2016-07-26
LT3299368T (lt) 2020-05-25
DK3299368T3 (da) 2020-05-25
SI3689865T1 (sl) 2023-07-31
KR102380539B1 (ko) 2022-03-29
IL244943A0 (en) 2016-05-31
DK3074386T3 (en) 2018-01-22
CN110172056B (zh) 2022-04-19
KR20220044370A (ko) 2022-04-07
HUE037588T2 (hu) 2018-09-28
DK3689865T3 (en) 2023-06-19
US20180251432A1 (en) 2018-09-06
HRP20200775T1 (hr) 2020-07-24
KR102421388B1 (ko) 2022-07-18
JP6342495B2 (ja) 2018-06-13
PE20160869A1 (es) 2016-09-08
CA2926908A1 (en) 2015-06-04
HK1252317A1 (zh) 2019-05-24
WO2015079417A1 (en) 2015-06-04
HRP20171999T1 (hr) 2018-02-09
US20160235746A1 (en) 2016-08-18
PH12016500791B1 (en) 2016-06-13
AU2014356069B2 (en) 2017-06-15
US20150152068A1 (en) 2015-06-04
LT3689865T (lt) 2023-07-10
NZ718835A (en) 2021-12-24
TN2016000128A1 (en) 2017-10-06
MA39055A1 (fr) 2018-02-28
LT3074386T (lt) 2017-12-27
TWI652261B (zh) 2019-03-01
PT3074386T (pt) 2017-11-15
MX367911B (es) 2019-09-11
EP3074386B1 (en) 2017-10-11
RS64275B1 (sr) 2023-07-31
EA201691125A1 (ru) 2016-09-30
EP3299368B1 (en) 2020-02-26
ES2947770T3 (es) 2023-08-18
CU24384B1 (es) 2019-03-04
MY191381A (en) 2022-06-22
ES2791525T3 (es) 2020-11-04
AP2016009158A0 (en) 2016-04-30
EP3689865A1 (en) 2020-08-05
JO3314B1 (ar) 2019-03-13
CL2016001055A1 (es) 2016-10-28
UY35858A (es) 2015-06-30
EP4219478A1 (en) 2023-08-02
BR112016010397B1 (pt) 2023-04-11
CN105683181A (zh) 2016-06-15
ZA201602275B (en) 2017-08-30
SI3299368T1 (sl) 2020-07-31
AU2014356069A1 (en) 2016-05-05
US20220041561A1 (en) 2022-02-10
JP2016538313A (ja) 2016-12-08
TW201609666A (zh) 2016-03-16
EP3299368A1 (en) 2018-03-28
HRP20230585T1 (hr) 2023-09-01
UA117256C2 (uk) 2018-07-10
SV2016005206A (es) 2016-11-21
BR112016010397A8 (pt) 2020-04-22

Similar Documents

Publication Publication Date Title
CY1119705T1 (el) Νεα παραγωγα αμινοπυριμιδινης
MX2014000338A (es) Derivados de pirrolo-pirimidina novedoso.
CY1121512T1 (el) Μεθοδοι και ενδιαμεσες ενωσεις για την παρασκευη αναστολεα jak
CY1118834T1 (el) Συγχωνευμενες ετεροκυκλικες ενωσεις ως αναστολεις πρωτεϊνικης κινασης
ECSP18032223A (es) PIRAZOLO[3,4-b]PIRIDIN-6-CARBOXAMIDAS N-SULFONILADAS Y MÉTODO DE USO
CY1121360T1 (el) Αναστολεις dna-pk
CY1120248T1 (el) Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου
EA202090258A3 (ru) Производные пирроло[3,2-d]пиримидина для лечения вирусных инфекций и других заболеваний
EA202090291A2 (ru) Производные бипиразола в качестве ингибиторов jak
BR112015009942A2 (pt) derivados de tiofeno fundidos tricíclicos como inibidores de jak
EA201590663A1 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ И ДРУГИХ ЗАБОЛЕВАНИЙ
EA201690303A1 (ru) ПРОИЗВОДНЫЕ ТИЕНО[3,2-d]ПИРИМИДИНОВ ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ
EA201690978A1 (ru) ПИРРОЛО[1.2-f][1.2.4]ТРИАЗИНЫ, ИСПОЛЬЗУЕМЫЕ ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНО-СИНЦИТИАЛЬНЫХ ВИРУСНЫХ ИНФЕКЦИЙ
EA201591524A1 (ru) Производные 2-аминопиримидина для лечения вирусных инфекций
CL2015003444A1 (es) Compuestos de 3,4 dihidroisoquinolin-2(1h)-ilo
BR112017011798A2 (pt) 4,6-substituído-pirazolo[1,5-a] pirazinas como inibidores janus cinase
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
MX2018011283A (es) Compuestos de cinnolin-4-amina y su uso en el tratamiento del cancer.
BR112015007974A2 (pt) compostos de carbamato fenil substituídos
EA201990834A1 (ru) Пиримидиновые пролекарства для лечения вирусных инфекций и других заболеваний
TH180843A (th) อนุพันธ์อะมิโน ไพริมิดีนชนิดใหม่
MX2016001747A (es) Derivados de difeniloxialquilamina y derivados de ariloxialquilamina, composicion farmaceutica, uso de dicha composicion farmaceutica para tratar, prevenir o inhibir enfermedades inflamatorias pulmonares cronicas y metodo para tratar o prevenir dichas enfermedades.